Autolus Therapeutics’ (AUTL) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report released on Friday,Benzinga reports. The firm currently has a $10.00 target price on the stock.

Several other brokerages have also weighed in on AUTL. Zacks Research upgraded shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. Truist Financial raised Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Weiss Ratings restated a “sell (d-)” rating on shares of Autolus Therapeutics in a report on Wednesday, January 21st. Finally, HC Wainwright initiated coverage on Autolus Therapeutics in a research note on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Autolus Therapeutics Stock Performance

Autolus Therapeutics stock opened at $1.21 on Friday. The company has a market cap of $322.03 million, a P/E ratio of -1.12 and a beta of 1.95. Autolus Therapeutics has a one year low of $1.11 and a one year high of $2.70. The business has a fifty day moving average of $1.49 and a two-hundred day moving average of $1.52.

Autolus Therapeutics (NASDAQ:AUTL) last posted its quarterly earnings results on Friday, March 27th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). The company had revenue of $24.29 million for the quarter, compared to analyst estimates of $23.92 million. Autolus Therapeutics had a negative return on equity of 87.75% and a negative net margin of 381.40%. Sell-side analysts predict that Autolus Therapeutics will post -0.94 EPS for the current year.

Institutional Trading of Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd grew its position in shares of Autolus Therapeutics by 334.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 123,279 shares of the company’s stock valued at $245,000 after purchasing an additional 94,873 shares during the last quarter. Invesco Ltd. raised its position in shares of Autolus Therapeutics by 35.7% during the 4th quarter. Invesco Ltd. now owns 51,642 shares of the company’s stock worth $103,000 after purchasing an additional 13,593 shares during the last quarter. Tudor Investment Corp ET AL lifted its stake in Autolus Therapeutics by 36.5% in the 4th quarter. Tudor Investment Corp ET AL now owns 282,113 shares of the company’s stock valued at $561,000 after buying an additional 75,460 shares in the last quarter. Armistice Capital LLC lifted its stake in Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after buying an additional 1,900,000 shares in the last quarter. Finally, Cetera Investment Advisers grew its holdings in Autolus Therapeutics by 37.3% during the 4th quarter. Cetera Investment Advisers now owns 1,099,750 shares of the company’s stock valued at $2,189,000 after buying an additional 298,500 shares during the last quarter. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Key Autolus Therapeutics News

Here are the key news stories impacting Autolus Therapeutics this week:

• Positive Sentiment: Company reiterated 2026 guidance: management expects AUCATZYL® net product revenue of $120–$135M and a shift to positive gross margin in 2026 — a clear path to improving unit economics and cash-generation visibility. Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts
• Positive Sentiment: Commercial traction: AUCATZYL reported ~$23.3M net product revenue in Q4 and $74.3M for FY2025; UK launch underway after positive NICE evaluation and real‑world data show favorable activity/safety — supports revenue ramp thesis. Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
• Positive Sentiment: Analyst upgrades/price target upside: Needham reaffirmed a Buy with a $10 PT (large theoretical upside from current levels) and Truist upgraded to Strong-Buy — these notes can attract speculative buying ahead of clinical readouts. Benzinga
• Neutral Sentiment: Pipeline catalyst timeline: pivotal Phase 2 trials enrolling in lupus nephritis and pediatric ALL; initial BOBCAT Phase 1 data in progressive MS expected late 2026 — potential upside but not immediate. Press Release
• Neutral Sentiment: Company hosted an earnings call and published the transcript/slides — useful for detail on margin assumptions and cash runway into Q4 2027. Q4 2025 Earnings Call Transcript
• Negative Sentiment: Earnings miss and weak profitability metrics: Q4 EPS of ($0.34) missed consensus ($0.27); company still deeply unprofitable with a large negative net margin and negative ROE — these metrics pressure sentiment in the near term. Press Release / Slide Deck
• Negative Sentiment: Analyst caution: Some outlets (and at least one analyst note) highlight a challenging risk/reward despite strong B-ALL data, citing reliance on upcoming autoimmune and pediatric data to re‑rate the stock. Seeking Alpha Hold-perspective

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.